Clinical Trial Update: A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ABP-671 for efficacy, safety, and pharmacokinetics in gout and hyperuricemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout
• Hyperuricemia

Drugs mentioned

• ABP-671

Snippet

Sponsor: Atom Therapeutics Co., Ltd | Conditions: Gout, Hyperuricemia | Phase 2 | Status: COMPLETED